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LDL-C: lower is better for longer—even at
low risk
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Abstract
Background: Low-density lipoprotein cholesterol (LDL-C) causes atherosclerotic disease, as demonstrated in
experimental and epidemiological cohorts, randomised controlled trials, and Mendelian randomisation studies.
Main text: There is considerable inconsistency between existing guidelines as to how to effectively manage
patients at low overall risk of cardiovascular disease (CVD) who have persistently elevated levels of LDL-C.
We propose a step-by-step practical approach for the management of cardiovascular risks in individuals with low
(< 1%) 10-year risk of CVD, and elevated (> 140 mg/dL, 3.6 mmol/L) LDL-C. The strategy proposed is based on the
level of adherence to lifestyle interventions (LSI), and in case of non-adherence, stepwise practical management,
including lipid-lowering therapy, is recommended to achieve a target LDL-C levels (< 115 mg/dL, 3.0 mmol/L).
Conclusions: Further studies are necessary to answer the questions on the long-term efficacy, safety, and cost-
effectiveness of the suggested approach. This is critical, considering the ever-increasing numbers of such low-risk
patients seen in clinical practice.
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Background
Low-density lipoprotein cholesterol (LDL-C) causes ath-
erosclerotic disease. This fact has been repeatedly dem-
onstrated in experimental studies, epidemiological
cohorts, randomised clinical trials of LDL-C lowering
drugs, and studies employing Mendelian randomisation
[1]. Notably, the gradient of the relationship between
LDL-C and outcomes of atherosclerotic disease becomes
steeper with increasing duration of follow-up (in epi-
demiological studies) and treatment (in intervention
trials). From this, it can be concluded that an individual’s
risk of atherosclerotic disease is strongly determined by
their cumulative lifelong exposure to LDL-C [1].
Accordingly, a significant long-term increased risk for
coronary heart disease (CHD) and cardiovascular
mortality has been reported in young adults with LDL-C
≥ 100 mg/dL (2.5 mmol/L) [2, 3]. Therefore, in order to
prevent atherosclerosis and its sequelae (myocardial in-
farction, ischemic stroke and peripheral arterial disease),
it is necessary to act early in life. Indeed, the early
manifestations of atherosclerosis are often apparent in
the third decade of life [4–7], a problem that is brought
into stark reality by the early morbidity and mortality
associated with familial hypercholesterolaemia (FH) [8].
Moreover, changes in plasma cholesterol levels have
been found to be directly associated with cardiovascular
disease (CVD) events in young adults [9]. Based on these
findings, it is clear that, with respect to LDL-C, ‘lower is
better, for longer’.
Main text
The risk of atherosclerotic CVD events and mortality
can be reduced by currently used drugs, which reduce
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circulating concentrations of LDC. These include statins
(which inhibit HMG-CoA reductase, the rate-limiting step
in hepatic endogenous cholesterol synthesis) [10–12], eze-
timibe (which inhibits the polytopic transmembrane pro-
tein, Niemann-Pick C1-Like 1, which is responsible for
cholesterol absorption from the jejunal brush border) [13],
and anti-proprotein convertase subtilisin/kexin type 9
(PCSK9) monoclonal antibodies (which inhibit PCSK9, a
regulatory protein that binds to LDL-receptors on hepato-
cytes and promotes their routing into lysosomes for pro-
teolytic destruction) [14, 15]. Intriguingly, inhibition of
HMG-CoA reductase, Niemann-Pick C1-Like 1 and
PCSK9 all increase the LDL-receptor density on the sur-
face of hepatocytes, which results in more extensive re-
moval of circulating LDL particles.
Because of the multifactorial nature of risk factors pre-
disposing to CVD, and in order to use lipid-lowering
drugs most effectively, reducing unnecessary cost and
exposure to adverse effects, national and international
guidelines make recommendations relating to the initi-
ation of lipid-lowering therapy based upon calculations
of cardiovascular risk, rather than lipid profile alone. Al-
though the specifics of the risk prediction tools and
thresholds differ between major guidelines, the approach
is essentially the same. The European Society of Cardi-
ology (ESC)/European Atherosclerosis Society (EAS)
[16] recommendations are based upon the SCORE 10-
year risk calculation [17] and consider both the overall
SCORE and the untreated circulating LDL-C concentra-
tion in determining whether drug interventions should
be employed [16]. In the UK, NICE recommends offer-
ing lipid modification therapy to people aged 84 years
and younger if their estimated 10-year risk of developing
CVD using the QRISK [18] assessment tool is 10% or
more and lifestyle modification is ineffective or inappro-
priate [19]. American College of Cardiology (ACC)/
American Heart Association (AHA) guidelines recom-
mend statin therapy when 10-year risk, calculated using
the pooled-cohort equations [20] exceeds 7.5% [21] (for
non-diabetics with LDL-C > 70 mg/dL [1.8 mmol/L] and
the presence of other risk enhancing factors).
However, 10-year predictions underestimate lifetime
risk and are driven to a large extent by age [22, 23].
Clinical guidelines based upon 10-year risk profiles are
prone to ignore younger patients with a single risk fac-
tor, which is unlikely to result in deleterious outcomes
in the forthcoming decade, but which epidemiological
evidence suggests is associated with an elevated inci-
dence of disease later in life [24]. This is perhaps justifi-
able for non-modifiable risk factors, but when multiple
strategies exist to ameliorate the associated risk, as
they do for LDL-C, then we are at risk of missing
opportunities to intervene now to improve health in
later life.
There is considerable inconsistency in approaches
used to manage patients at overall low risk of CVD
(< 1%) who have persistently elevated levels of LDL-C
(115mg/dL [3mmol/L]–190mg/dL [4.9mmol/L]). In the
2016 ESC/EAS guidelines for the management of dyslipi-
daemias, no intervention was recommended until LDL-C
reached 190mg/dL (4.9mmol/L) [25], which was a matter
of considerable debate and presented problems in
everyday clinical practice. In the 2019 recommenda-
tions, lifestyle modifications are suggested initially, and
pharmacological interventions can be now considered for
individuals with LDL-C above 115mg/dL (3mmol/L)
[16].
We propose a more detailed approach to the ma-
nagement of cardiovascular risks in individuals with low
(< 1%) 10-year risk of CVD, but elevated (> 140 mg/dL,
3.6 mmol/L) LDL-C (Fig. 1). The cutoff point of 140mg/
dL (3.6 mmol/L) results from the calculations of the pos-
sibility of LDL-C reduction to the target level of 115mg/
dL (3 mmol/L) with the adherent lifestyle changes; this
level also appeared in the previous 2017 ESC/EAS task
force on practical clinical guidance for PCSK9 inhibitors
application in patients with atherosclerotic CVD, where
the persistent LDL-C level of > 140 mg/dL (3.6 mmol/L;
on statins and ezetimibe) was an independent risk factor
linked to significantly increased CVD risk, requiring
consideration of PCSK9 inhibitors [26]. The strategy
proposed in this paper is largely based upon evidence-
based interventions to reduce LDL-C, rather than the
ideal endpoints of major adverse cardiovascular events
(MACE) and mortality. In this regard, the strong-graded
relationship between LDL-C and mortality seen across
many hundreds of studies [1], and the availability of very
large well-conducted epidemiological datasets means
that it is appropriate to base recommendations on stud-
ies employing LDL-C reduction as the primary endpoint.
The potential benefits of this approach are highlighted
by a recent study which quantified the relative import-
ance of risk factors for CHD. Amongst a population of
22,626 individuals, aged 45–85, the population attribut-
able fraction (PAF) was found to be 17% (95% CI 10.2–
23.2) for non-HDL-C > 130mg/dl. However, in the sub-
population of individuals aged 45–54, the PAF was
32.8% (95% CI 10.1–49.9), suggesting a large proportion
of coronary heart disease might be eliminated by optimal
lipid-management in younger individuals [27].
The first and most important approach to low 10-year
risk individuals is to provide education and information
relating to the benefits of lifestyle interventions (LSI).
The dietary approach to LDL-C reduction includes the
promotion of a well-balanced diet, which derives a low
proportion of energy from saturated fatty acids [28], and
a high proportion from polyunsaturated fatty acids [29].
ESC/EAS guidelines suggest that carbohydrate intake
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should range between 45 and 55% of total energy intake
and that intake of added sugar should not exceed 10% of
total energy [16]. In the short-term, low-carbohydrate
diets (LCD) [30] improve lipid profile, although a recent
well-designed investigation found a potentially unfavour-
able association of LCD with overall and cause-specific
mortality, based on both analyses of an established co-
hort and by pooling previous cohort studies in a meta-
analysis [31, 32]. Dietary fibre (particularly when it re-
places saturated fat in the diet) has beneficial effects on
plasma lipid profile [33]. The benefits of smoking cessa-
tion [34], exercise [35], and weight reduction [35], on
cardiovascular risk, are more closely associated with ele-
vation of HDL-C and reduction of triglycerides, than
reduction of LDL-C, but these strategies should neverthe-
less be encouraged in all individuals, especially those with
any risk factors for CVD [16, 25].
For those individuals who manage good adherence to
LSI (indicated by a reduction of LDL-C by 20–25%/28–
35mg/dl = achieved LDL-C ≤ 115 mg/dL [3 mmol/L]),
annual check-up to monitor cardiovascular risk and
reinforce messages about LSI are appropriate. For indi-
viduals with moderate success at reducing LDL-C using
LSI (indicated by LDL-C > 115mg/dL [3 mmol/L] but
close to target and < 140 mg/dL [3.6 mmol/L]), more
frequent monitoring (preferably every 12 weeks) is ap-
propriate, and these individuals may benefit from en-
hanced educational interventions. Where adherence to
LSI is poor (indicated by LDL-C > 140mg/dL [3.6
mmol/L]), nutraceuticals/nutraceutical combination [36]
and/or low-dose statin therapy and/or ezetimibe (espe-
cially in those with statin-related muscle symptoms or
not willing to use statins) in combination with continued
LSI might be warranted in order to reach the recom-
mended LDL-C goals. This three-arm practical manage-
ment is based on the real-world adherence to lifestyle
changes, which is usually only 25–30%, and even worse
in patients in primary prevention [37, 38]. Real-world
adherence to lipid-lowering therapy is also suboptimal
and poor adherence is associated with worse CVD
outcomes [39].
Recent position papers produced by the International
Lipid Expert Panel [40–42] and other Scientific Societies
[43] have summarised the evidence relating to the
cholesterol-lowering effects of nutraceuticals in general
[41, 42] and in the specific situation of statin intolerance
[40]. A wide range of nutraceuticals, alone or in combin-
ation therapy, have been shown to have favourable
Fig. 1 Proposed approach to the management of cardiovascular risks in individuals with low (< 1%) 10-year risk of cardiovascular disease, but
elevated (> 140mg/dL, 3.6 mmol/L) LDL-C
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effects on lipid profiles. However, nutraceuticals are
often evaluated in much smaller studies than phase 3
evaluations of conventional pharmaceuticals. Further-
more, variation in product composition between differ-
ent preparations of similarly named nutraceuticals can
lead to heterogeneity of response. Thus, the evidence
basis for the safety and efficacy of nutraceuticals is gen-
erally less strong than conventional pharmaceuticals.
The role of nutraceuticals should not be to replace con-
ventional pharmaceuticals in settings where they have
been shown to be effective, but to optimise treatment
when lipid targets are not met. Lipid-lowering nutraceu-
ticals include red yeast rice (with confirmed production
quality/citrinin-free), bergamot, berberine, policosanol,
artichoke, soluble fibre, and plant sterols and stanols
[40, 44]. Although the LDL-C reductions elicited by
these agents are generally modest compared with high-
intensity statins and PCSK9-inhibitors, nevertheless, the
‘lower is better for longer’ approach to cardiovascular
risk-reduction implies that a small reduction of LDL-C
sustained over a long period of time would be expected
to accrue a substantial benefit in terms of CVD risk re-
duction. This latter interpretation is supported by the
observation that ezetimibe therapy, despite producing a
relatively mild LDL-C lowering, also caused a significant
reduction of CVD risk [13, 45]. Finally, when LDL-C re-
mains > 115mg/dl (3.0 mmol/L), despite LSI, and even-
tually nutraceuticals, statin and/or ezetimibe [41, 45]
therapy should be considered. In the opinion of the au-
thors, there is no need for a more intensive approach for
low-risk patients, particularly as we do not have enough
data on the effectiveness of such an approach in redu-
cing CVOT. Furthermore, the potential for increased
risk of statin-related adverse effects would clearly not be
desirable and might influence the effectiveness of later
therapy in this group of patients.
Conclusions
In summary, even mild LDL-C elevations at a young age
elevate CVD risk and are likely to have a greater un-
favourable prognostic impact than similar elevations in
older individuals, as has been recently confirmed [46].
Commonly used 10-year CVD risk scores are insuffi-
ciently sensitive to detect long-term CV risk in younger
individuals. The recent recommendation by the ACC/
AHA [21] to use lifetime risk scores in younger patients
is pragmatic and sensible. The use of systems highlight-
ing the long-term CV risk in younger individuals is de-
sirable [47, 48], and practical strategies combining LSI,
nutraceuticals, statins, and ezetimibe (as proposed in this
commentary) should be used to modify elevated lifetime
risk when it is detected. With respect to LDL-C, we
know that ‘lower is better for longer’; therefore, we must
allow this knowledge to be used to help those subjects
(currently) at ‘low CVD risk’. Individuals who undertake
approaches to reduce lipids at a lower age can benefit
from a lower life-long exposure to LDL-C.
It is also important to emphasise that the unmet need
for prevention and suitable treatment for these patients
is likely to grow (with increasing numbers of such
patients in the everyday clinical practice). Additionally,
because of the paucity of data, well-designed studies are
still necessary in order to answer the questions on the
efficacy, safety, and cost-effectiveness of long-term inter-
ventions to reduce LDL-C in low-risk populations.
Moreover, with the suggested approach, which is driven
by changes in lifestyle, we emphasise the critical import-
ance of non-pharmacological interventions, not only for
those at high and very high risk, but equally (or, perhaps,
more importantly) for those at low cardiovascular risk.
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